BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 16, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2024

View Archived Issues
Syringe with illustration of molecules

Working backward from the goal is promising HIV vaccine strategy

Last week, the 2024 meeting of the International AIDS Society (IAS) was wrapping up as the 2024 Olympic Games were about to begin. That timing was probably what prompted the use of multiple sports analogies at Thursday’s plenary session on HIV prevention strategies. Given the decades-long attempts at developing an HIV vaccine, Peter Piot, past IAS president and director emeritus and professor at the London School of Hygiene and Tropical Medicine, said in his introduction: “This is clearly a marathon. But marathons also finish.” Read More

Enzyme inhibitor helps cardiomyocytes relax

Researchers from the University of Pennsylvania have successfully inhibited vasohibin enzymes (VASH) with SVC-01 and SVC-02 in the ZSF1 obese rat model of heart failure with preserved ejection fraction (HFpEF). Read More
Mouse neuron.

PDE7 inhibition reduces stress-induced behavioral and neuronal changes in mice

Researchers from Qingdao University and affiliated organizations announced data from a preclinical study using the phosphodiesterase 7 (PDE7) inhibitor BRL-50481 to assess the involvement of PDE7 in the stress-induced behavioral and neuron morphological changes. Read More
Art concept for pain

Novel CCR2-targeting pepducin alleviates neuropathic and bone cancer pain

Researchers from Universite de Sherbrooke and University of California San Francisco presented the discovery and preclinical characterization of CCR2-targeting pepducin, PP-101. Read More

Insilico Medicine patents new HPK1 inhibitors

Insilico Medicine Inc. has prepared and tested new spirocyclic mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer and viral infections. Read More
Piggy bank filled with dollar coins

Confo financing will in part bring two compounds to IND

G protein-coupled receptor (GPCR) drug discovery and development specialist Confo Therapeutics NV has closed a €60 million (US$65.2 million) series B round that will fund a significant expansion of the inhouse portfolio while it continues to turn the handle on its technology platform to generate more compounds for partnering. Read More

‘We're always on the lookout for what's next’

From no hope to viable treatments, BioWorld  is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld  team is ‘always on the lookout for what's next.’ Read More

Nanjing Sanhome Pharmaceutical identifies CDK12/13 inhibitors

Cyclin-dependent kinase 12 (CDK12)/cyclin K and CDK13/cyclin K inhibitors have been described in a Nanjing Sanhome Pharmaceutical Co. Ltd. patent and are reported to be potentially useful for the treatment of cancer. Read More

Suzhou Puhe Biopharma discloses new WRN inhibitors for cancer

A Suzhou Puhe Biopharma Co. Ltd. patent reports new Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors described as potentially useful for the treatment of cancer. Read More
Colorful illustration of the heart

EDG-7500 improves diastolic performance in animal models of pacing induced LV systolic dysfunction

Researchers from Edgewise Therapeutics Inc. presented preclinical data for the cardiac sarcomere modulator, EDG-7500, which is being developed for the treatment of hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction. Read More

New CDK2 inhibitors presented in Blueprint Medicines patent

Blueprint Medicines Corp. has identified cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer. Read More

The Shanghai Institute of Materia Medica describes new ERRα inverse agonists

Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has discovered estrogen-related receptor α (ERRα; ERR1) inverse agonists reported to be useful for the treatment of cancer, obesity, hypertension, gallstone, osteoporosis, metabolic syndrome, hyperuricemia and Alzheimer's disease. Read More
Conceptual image for brain cancer treatment

FERMT1 reduces stemness, shows promise as glioma biomarker

Fermitin family homolog 1 (FERMT1), a member of the kindlin family of focal adhesion proteins, plays a pivotal role in mediating integrin-dependent cell adhesion and signaling. Scientists at Fujian Medical University (FJMU) assessed the functional significance of FERMT1 in glioma progression and stemness.  Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 16, 2026.
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing